[1]
|
Koro, C.E., Bo, H.L. and Bowlin, S.J. (2009) Antidiabetic Medication Use and Prevalence of Chronic Kidney Disease among Patients with Type 2 Diabetes Mellitus in the United States. Clinical Therapeutics, 31, 2608-2617.
https://doi.org/10.1016/j.clinthera.2009.10.020
|
[2]
|
Alicic, R.Z., Rooney, M.T. and Tuttle, K.R. (2017) Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12, 2032-2045.
https://doi.org/10.2215/CJN.11491116
|
[3]
|
Jankowski, J., Floege, J., Fliser, D., et al. (2021) Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation, 143, 1157-1172.
https://doi.org/10.1161/CIRCULATIONAHA.120.050686
|
[4]
|
Agodoa, L. (2000) United States Renal Data System (USRDS). Nefrologia, 20, 13-16.
|
[5]
|
Saez, M., Vizcaya, D., Vizcaya, D., et al. (2021) Incidence and Risk Factors for Mortality and End-Stage Renal Disease in People with Type 2 Diabetes and Diabetic Kidney Disease: A Pop-ulation-Based Cohort Study in the UK. BMJ Open Diabetes Research & Care, 9, e002146. https://doi.org/10.1136/bmjdrc-2021-002146
|
[6]
|
Rajiv, A., Anker, S.D., George, B., et al. (2020) Investigating New Treatment Opportunities for Patients with Chronic Kidney Disease in Type 2 Diabetes: The Role of Finerenone. Nephrology Dialysis Transplantation, 37, 1014-1023.
|
[7]
|
Bauersachs, J., Frédéric, J. and Toto, R. (2015) Mineralo-corticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hy-pertension, 65, 257-263.
https://doi.org/10.1161/HYPERTENSIONAHA.114.04488
|
[8]
|
Brown, N.J. (2013) Contribution of Aldosterone to Cardiovascular and Renal Inflammation and Fibrosis. Nature Reviews Nephrology, 9, 459-469. https://doi.org/10.1038/nrneph.2013.110
|
[9]
|
Buonafine, M., Bonnard, B. and Jaisser, F. (2018) Mineralocorticoid Receptor and Cardiovascular Disease. American Journal of Hypertension, 31, 1165-1174. https://doi.org/10.1093/ajh/hpy120
|
[10]
|
Gomez-Sanchez, E. and Gomez-Sanchez, C.E. (2014) The Multifaceted Mineralocorticoid Receptor. Comprehensive Physiology, 4, 965-994. https://doi.org/10.1002/cphy.c130044
|
[11]
|
Ong, G. and Young, M. (2017) Mineralocorticoid Regulation of Cell Function: The Role of Rapid Signalling and Gene Transcription Pathways. Journal of Molecular Endocrinology, 58, R33-R57.
https://doi.org/10.1530/JME-15-0318
|
[12]
|
Shibata, S., Nagase, M., Yoshida, S., et al. (2008) Modification of Mineralocorticoid Receptor Function by Rac1 GTPase: Implication in Proteinuric Kidney Disease. Nature Medicine, 14, 1370-1376. https://doi.org/10.1038/nm.1879
|
[13]
|
Brem, A. and Gong, R. (2015) Therapeutic Targeting of Aldos-terone: A Novel Approach to the Treatment of Glomerular Disease. Clinical Science, 128, 527-535. https://doi.org/10.1042/CS20140432
|
[14]
|
van der Heijden, C., Deinum, J., Joosten, L., et al. (2018) The Mineral-ocorticoid Receptor as a Modulator of Innate Immunity and Atherosclerosis. Cardiovascular Research, 114, 944-953.
https://doi.org/10.1093/cvr/cvy092
|
[15]
|
Barrera-Chimal, J., Lima-Posada, I., Bakris, G.L., et al. (2017) Mineral-ocorticoid Receptor Antagonists in Diabetic Kidney Disease—Mechanistic and Therapeutic Effects. Nature Reviews Nephrology, 18, 56-70.
|
[16]
|
Barrera-Chimal, J., Girerd, S. and Jaisser, F. (2019) Mineralocorticoid Receptor Antago-nists and Kidney Diseases: Pathophysiological Basis. Kidney International, 96, 302-319. https://doi.org/10.1016/j.kint.2019.02.030
|
[17]
|
Mi, B., Ying, C., Min, Z., et al. (2017) NLRP3 Inflammasome Ac-tivation Contributes to Aldosterone-Induced Podocyte Injury. American Journal of Physiology-Renal Physiology, 312, F556-F564.
https://doi.org/10.1152/ajprenal.00332.2016
|
[18]
|
Shibata, S., Nagase, M., Yoshida, S., et al. (2007) Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1. Hypertension, 49, 355-364. https://doi.org/10.1161/01.HYP.0000255636.11931.a2
|
[19]
|
Diah, S., Zhang, G.X., Nagai, Y., et al. (2008) Aldos-terone Induces Myofibroblastic Transdifferentiation and Collagen gene Expression through the Rho-Kinase Dependent Signaling Pathway in Rat Mesangial Cells. Experimental Cell Research, 314, 3654-3662. https://doi.org/10.1016/j.yexcr.2008.09.018
|
[20]
|
Mathew, J.T., Patni, H., Chaudhary, A.N., et al. (2008) Aldos-terone Induces Mesangial Cell Apoptosis Both in Vivo and in Vitro. American Journal of Physiology-Renal Physiology, 295, 73-81.
https://doi.org/10.1152/ajprenal.00435.2007
|
[21]
|
Huang, L.L., Nikolic-Paterson, D.J., et al. (2014) Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease. Journal of the American Society of Nephrology, 25, 2231-2240.
https://doi.org/10.1681/ASN.2012111094
|
[22]
|
Kolkhof, P., Delbeck, M., Kretschmer, A., et al. (2014) Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects from Rat Cardiorenal Injury. Journal of Cardiovascular Pharmacology, 64, 69-78.
https://doi.org/10.1097/FJC.0000000000000091
|
[23]
|
Platt, D. and Pauli, H. (1972) Studies on Organ- and Sub-cellular Distribution of 3 H-Spironolactone in Animals. Arzneimittel-Forschung/Drug Research, 22, 1801-1802.
|
[24]
|
Food and Drug Administration (2021) KERENDIA (Finerenone) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf
|
[25]
|
Pitt, B., Filippatos, G., Agarwal, R., et al. (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England Journal of Medicine, 385, 2252-2263. https://doi.org/10.1056/NEJMoa2110956
|
[26]
|
Agarwal, R., Joseph, A., Anker, S.D., et al. (2022) Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. Journal of the American Society of Nephrology, 33, 225-237. https://doi.org/10.1681/ASN.2021070942
|